Nova Pharma Solutions Bhd (XKLS:03006) ROCE % : 31.86% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Nova Pharma Solutions Bhd ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nova Pharma Solutions Bhd's annualized ROCE % for the quarter that ended in Dec. 2023 was 31.86%.

Nova Pharma Solutions Bhd ROCE % Historical Data

The historical data trend for Nova Pharma Solutions Bhd's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Pharma Solutions Bhd ROCE % Chart

Nova Pharma Solutions Bhd Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

11.21

-6.88

5.54

13.68

38.45

Nova Pharma Solutions Bhd Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial											9.16	20.70	6.35	43.92	31.86

Nova Pharma Solutions Bhd ROCE % Calculation

Nova Pharma Solutions Bhd's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	4.916	/	( ( (13.882 - 2.613)	+	(17.337 - 3.034) )	/ 2 )
	=	4.916	/	( (11.269	+	14.303)	/ 2 )
	=	4.916	/	12.786
	=	38.45 %

Nova Pharma Solutions Bhd's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	4.414	/	( ( (16.869 - 3.465)	+	(17.337 - 3.034) )	/ 2 )
	=	4.414	/	( ( 13.404	+	14.303 )	/ 2 )
	=	4.414	/	13.8535
	=	31.86 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Nova Pharma Solutions Bhd (XKLS:03006) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nova Pharma Solutions Bhd ROCE % Related Terms

Thank you for viewing the detailed overview of Nova Pharma Solutions Bhd's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Pharma Solutions Bhd (XKLS:03006) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Construction » Nova Pharma Solutions Bhd (XKLS:03006) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Jalan USJ 25/1, Level 5, Suite C-5-1 & 2, Block C, Sky Park, One City, Subang Jaya, SGR, MYS, 47650

Website

http://www.novapharmasolutions.com

Nova Pharma Solutions Bhd provides engineering solutions to pharma and biotech industries. The company's reportable segments include Design fee, Post Design, & Other support fees. Design fee comprises conceptual designs which include user requirement specification, capacity analysis and process scheduling with detailed costing, list of deliverables, details specification of various equipment and processes. Post design fee comprise tendering and procurement support as well as the construction of a plant, & Other support fees comprise of services to assist a customer in the good manufacturing practice document review & gap analysis and assessment. It generates a majority of its revenue from the Design fee segment. Geographically, the company generates a majority of its revenue from Malaysia.

Nova Pharma Solutions Bhd (XKLS:03006) Headlines

No Headlines